Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2016

Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2016
Published Jul 20, 2016
95 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2016, provides an overview of the Uterine Leiomyoma (Uterine Fibroids) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids)
- The report reviews pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Uterine Leiomyoma (Uterine Fibroids) therapeutics and enlists all their major and minor projects
- The report assesses Uterine Leiomyoma (Uterine Fibroids) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key

  
Source:
Document ID
GMDHC8278IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Uterine Leiomyoma (Uterine Fibroids) Overview81
Therapeutics Development92
  Pipeline Products for Uterine Leiomyoma (Uterine Fibroids) Overview91
  Pipeline Products for Uterine Leiomyoma (Uterine Fibroids) Comparative Analysis101
Uterine Leiomyoma (Uterine Fibroids) Therapeutics under Development by Companies111
Uterine Leiomyoma (Uterine Fibroids) Therapeutics under Investigation by Universities/Institutes121
Uterine Leiomyoma (Uterine Fibroids) Pipeline Products Glance133
  Late Stage Products131
  Clinical Stage Products141
  Early Stage Products151
Uterine Leiomyoma (Uterine Fibroids) Products under Development by Companies161
Uterine Leiomyoma (Uterine Fibroids) Products under Investigation by Universities/Institutes171
Uterine Leiomyoma (Uterine Fibroids) Companies Involved in Therapeutics Development1810
  AbbVie Inc.181
  Addex Therapeutics Ltd191
  Bayer AG201
  BioSpecifics Technologies Corp.211
  Dongkook Pharmaceutical Co., Ltd.221
  Euroscreen S.A.231
  Kissei Pharmaceutical Co., Ltd.241
  Laboratoire HRA Pharma251
  Repros Therapeutics Inc.261
  Takeda Pharmaceutical Company Limited271
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Assessment289
  Assessment by Monotherapy Products281
  Assessment by Target292
  Assessment by Mechanism of Action312
  Assessment by Route of Administration332
  Assessment by Molecule Type352
Drug Profiles3743
  collagenase clostridium histolyticum Drug Profile3713
  Drug to Activate Progesterone Receptor for Uterine Fibroids Drug Profile501
  Drugs for Endometriosis and Uterine Fibroids Drug Profile511
  elagolix sodium Drug Profile524
  ESN-364 Drug Profile562
  EVE-104 Drug Profile581
  KLH-2109 Drug Profile591
  relugolix Drug Profile602
  Small Molecule to Antagonize FSH Receptor for Women's Health Drug Profile621
  Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology Drug Profile631
  telapristone acetate Drug Profile648
  triptorelin biosimilar Drug Profile721
  ulipristal acetate Drug Profile734
  vilaprisan Drug Profile771
  VPE-001 Drug Profile781
  VPEA-004 Drug Profile791
Uterine Leiomyoma (Uterine Fibroids) Dormant Projects801
Uterine Leiomyoma (Uterine Fibroids) Discontinued Products811
Uterine Leiomyoma (Uterine Fibroids) Product Development Milestones8212
  Featured News &Press Releases821
    May 31, 2016: BioSpecifics Technologies Announces Publication of Encouraging Data for Uterine Fibroid Treatment with CCH in American Journal of Obstetrics &Gynecology821
    May 18, 2016: Repros Reports Positive Clinical Data for Oral Proellex in Women With Severe Menstrual Bleeding Due to Uterine Fibroids821
    May 09, 2016: Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids831
    Apr 12, 2016: Repros Reports Positive Clinical Data for Vaginal Proellex in Women With Severe Menstrual Bleeding Due to Uterine Fibroids841
    Jan 28, 2016: AbbVie Initiates Enrollment in Phase 3 Clinical Program for Elagolix in Patients with Uterine Fibroids851
    Dec 21, 2015: Repros Updates Proellex Program861
    Nov 12, 2015: Repros Therapeutics Completes Randomization of Phase 2b Study of Vaginal Proellex in Women With Symptomatic Uterine Fibroid Bleeding861
    Oct 09, 2015: Full Results of PEARL IV Study Presented at the European Society of Gynaecological Endoscopy Congress Confirms the Efficacy of Ulipristal Acetate 5 mg for the Long Term Management of Uterine Fibroids871
    Sep 16, 2015: Abbvie Announces Plans To Proceed To Phase 3 Evaluation Of Elagolix In Patients With Uterine Fibroids881
    May 28, 2015: European Commission approves Esmya 5 mg for intermittent treatment in the long term management of Uterine Fibroids (myomas)891
    Apr 21, 2015: Euroscreen starts in parallel two Phase 2 clinical trials with ESN364 in UF and PCOS patients901
    Mar 24, 2015: Bayer to present new preclinical, early clinical and epidemiological data on Vilaprisan at 62nd Annual Scientific Meeting, March 25-28, 2015, in San Francisco, CA901
    Dec 29, 2014: Repros Initiates Two Phase 2B Uterine Fibroid Studies911
    Oct 16, 2014: BioSpecifics Technologies Announces Presentation of Encouraging Preclinical Data for CCH from Collaborative Uterine Fibroid Study with Duke Medicine921
    Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting922
Appendix942
  Methodology941
  Coverage941
  Secondary Research941
  Primary Research941
  Expert Panel Validation941
  Contact Us941
  Disclaimer951

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Uterine-Leiomyoma-Uterine-Fibroids-Pipeline-Review-H2-2016-2088-16243>
  
APA:
Global Markets Direct - Market Research. (2016). Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Uterine-Leiomyoma-Uterine-Fibroids-Pipeline-Review-H2-2016-2088-16243>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.